2023 was a tricky year to the biopharma industry, with numerous businesses downsizing and restructuring their workforces to stay afloat. There are signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace in the latter A part of 2023 and have continued their https://sites.google.com/view/bio-sites/blog